[go: up one dir, main page]

EP3331860B1 - Acides indanylaminopyridylcyclopropanecarboxyliques leurs compositions pharmaceutiques et leurs utilisations - Google Patents

Acides indanylaminopyridylcyclopropanecarboxyliques leurs compositions pharmaceutiques et leurs utilisations Download PDF

Info

Publication number
EP3331860B1
EP3331860B1 EP16750134.5A EP16750134A EP3331860B1 EP 3331860 B1 EP3331860 B1 EP 3331860B1 EP 16750134 A EP16750134 A EP 16750134A EP 3331860 B1 EP3331860 B1 EP 3331860B1
Authority
EP
European Patent Office
Prior art keywords
group
alkyl
cycloalkyl
replaced
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16750134.5A
Other languages
German (de)
English (en)
Other versions
EP3331860A1 (fr
Inventor
Matthias Eckhardt
Stefan Peters
Holger Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP3331860A1 publication Critical patent/EP3331860A1/fr
Application granted granted Critical
Publication of EP3331860B1 publication Critical patent/EP3331860B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel indanylaminopyridylcyclopropanecarboxylic acids, that are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR 1), to processes for their preparation, to pharmaceutical compositions containing these compounds and to their medical use for the prophylaxis and/or treatment of diseases which can be influenced by the modulation of the function of GPR40.
  • GPR40 also known as free fatty acid receptor FFAR 1
  • the pharmaceutical compositions of the invention are suitable for the prophylaxis and/or therapy of metabolic diseases, such as diabetes, more specifically type 2 diabetes mellitus, and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia.
  • Metabolic diseases are diseases caused by an abnormal metabolic process and may either be congenital due to an inherited enzyme abnormality or acquired due to a disease of an endocrine organ or failure of a metabolically important organ such as the liver or the pancreas.
  • Diabetes mellitus is a disease state or process derived from multiple causative factors and is defined as a chronic hyperglycemia associated with resulting damages to organs and dysfunctions of metabolic processes. Depending on its etiology, one differentiates between several forms of diabetes, which are either due to an absolute (lacking or decreased insulin secretion) or to a relative lack of insulin. Diabetes mellitus Type I (IDDM, insulin-dependent diabetes mellitus) generally occurs in adolescents under 20 years of age. It is assumed to be of auto-immune etiology, leading to an insulitis with the subsequent destruction of the beta cells of the islets of Langerhans which are responsible for the insulin synthesis. In addition, in latent autoimmune diabetes in adults ( LADA; Diabetes Care.
  • beta cells are being destroyed due to autoimmune attack.
  • the amount of insulin produced by the remaining pancreatic islet cells is too low, resulting in elevated blood glucose levels (hyperglycemia).
  • Diabetes mellitus Type II generally occurs at an older age. It is above all associated with a resistance to insulin in the liver and the skeletal muscles, but also with a defect of the islets of Langerhans. High blood glucose levels (and also high blood lipid levels) in turn lead to an impairment of beta cell function and to an increase in beta cell apoptosis.
  • Persistent or inadequately controlled hyperglycemia is associated with a wide range of pathologies. Diabetes is a very disabling disease, because today's common antidiabetic drugs do not control blood sugar levels well enough to completely prevent the occurrence of high and low blood sugar levels. Out of range blood sugar levels are toxic and cause long-term complications for example retinopathy, renopathy, neuropathy and peripheral vascular disease. There is also a host of related conditions, such as obesity, hypertension, stroke, heart disease and hyperlipidemia, for which persons with diabetes are substantially at risk.
  • Obesity is associated with an increased risk of follow-up diseases such as cardiovascular diseases, hypertension, diabetes, hyperlipidemia and an increased mortality.
  • Diabetes (insulin resistance) and obesity are part of the "metabolic syndrome” which is defined as the linkage between several diseases (also referred to as syndrome X, insulin-resistance syndrome, or deadly quartet). These often occur in the same patients and are major risk factors for development of diabetes type II and cardiovascular disease. It has been suggested that the control of lipid levels and glucose levels is required to treat diabetes type II, heart disease, and other occurrences of metabolic syndrome (see e.g., Diabetes 48: 1836-1841, 1999 ; JAMA 288: 2209-2716, 2002 ).
  • the free fatty acid receptor GPR40 (also referred to as either FFAR, FFAR1, or FFA1) is a cell-surface receptor and a member of the gene superfamily of G-protein coupled receptors, which was first identified as a so-called orphan receptor, i.e. a receptor without a known ligand, based on the predicted presence of seven putative transmembrane regions in the corresponding protein ( Sawzdargo et al. (1997) Biochem. Biophys. Res. Commun. 239: 543-547 ).
  • GPR40 is found to be highly expressed in several particular cell types: the pancreatic ⁇ cells and insulin-secreting cell lines, as well as in enteroendocrine cells, taste cells, and is reported to be expressed in immune cells, splenocytes, and in the human and monkey brain.
  • fatty acids of varying chain lengths are thought to represent the endogenous ligands for GPR40, activation of which is linked primarily to the modulation of the Gq family of intra-cellular signaling G proteins and concomitant induction of elevated calcium levels, although activation of Gs- and Gi-proteins to modulate intracellular levels of cAMP have also been reported.
  • GPR40 is activated especially by long-chain FFA, particularly oleate, as well as the PPAR-gamma agonist rosiglitazone.
  • GPR40 agonists may have the potential to restore or preserve islet function, therefore, GPR40 agonists may be beneficial also in that that they may delay or prevent the diminution and loss of islet function in a Type 2 diabetic patient.
  • GLP-1 glucagon-like peptide- 1
  • GIP glycose-dependent insulinotropic peptide; also known as gastric inhibitory peptide
  • GPR40 modulators may contribute to enhanced insulin release from the pancreatic beta cells also indirectly by e.g. a synergistic effect of GLP-1 and possibly GIP on the insulin release, and the other release incretins may also contribute to an overall beneficial contribution of GPR40 modulation on metabolic diseases.
  • the indirect contributions of GPR40 modulation on insulin release through the elevation of plasma levels of incretins may be further augmented by the coadministration of inhibitors of the enzymes responsible for the incretin degradation, such as inhibitors of DPP-4.
  • GPR40 in modulating insulin secretion indicates the therapeutic agents capable of modulating GPR40 function could be useful for the treatment of disorders such as diabetes and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia.
  • EP 1 726 580 discloses aminophenylpropanoic acid derivatives showing GRP40 receptor agonist activity.
  • WO 2015/024526 describes certain carboxylic acid compounds for modulating the GPR40 receptor function.
  • the object of the present invention is to provide new compounds, hereinafter described as compounds of formula I, in particular new indanylaminopyridylcyclopropanecarboxylic acids, which are active with regard to the G-protein-coupled receptor GPR40, notably are agonists of the G-protein-coupled receptor GPR40.
  • a further object of the present invention is to provide new compounds, in particular new indanylaminopyridylcyclopropanecarboxylic acids, which have an activating effect on the G-protein-coupled receptor GPR40 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
  • a further object of the present invention is to provide effective GPR40 agonists, in particular for use in the treatment of metabolic disorders, for example diabetes, dyslipidemia and/or obesity.
  • a further object of the present invention is to provide compounds for use in methods for treating a disease or condition mediated by the activation the G-protein-coupled receptor GPR40.
  • a further object of the present invention is to provide a pharmaceutical composition comprising at least one compound according to the invention.
  • a further object of the present invention is to provide a combination of at least one compound according to the invention with one or more additional therapeutic agents.
  • GPR40 modulators are known in the art, for example, the compounds disclosed in WO 2004/041266 ( EP 1 559 422 ), WO 2007/033002 , WO 2009/157418 , and WO 2013/178575 .
  • the indanylaminopyridylcyclopropanecarboxylic acids of the present invention provides one or more of the following advantages: enhanced potency, high metabolic and/or chemical stability, high selectivity and tolerability, enhanced solubility, and the possibility to form stable salts.
  • the invention relates to a compound of formula wherein
  • extension -Gn used within the definitions is meant to identify genus n of the respective substituent.
  • R-G1 defines genus 1 of the substituent R.
  • F atoms optionally substituted with 1 or more F atoms
  • none or one up to successively all H atoms bound to carbon atoms of the respective group or submoiety may be replaced by F atoms, preferably 1 to 5 H atoms or, more preferred, 1 to 3 H atoms may be replaced by F atoms.
  • this invention relates to a pharmaceutical composition, comprising one or more compounds of general formula I or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more inert carriers and/or diluents.
  • this description relates to a method for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR40 in a patient in need thereof characterized in that a compound of general formula I or a pharmaceutically acceptable salt thereof is administered to the patient.
  • a method for treating a metabolic disease or disorder such as diabetes, dyslipidemia and/or obesity, in a patient in need thereof characterized in that a therapeutically effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof is administered to the patient.
  • this description relates to a method for treating a disease or condition mediated by the activation of the G-protein-coupled receptor GPR40 in a patient that includes the step of administering to the patient in need of such treatment a therapeutically effective amount of a compound of the general formula I or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more additional therapeutic agents.
  • this invention relates to the use of a compound of the general formula I or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents for the treatment of diseases or conditions which are mediated by the activation of the G-protein-coupled receptor GPR40.
  • this invention relates to a pharmaceutical composition which comprises a compound according to general formula I or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.
  • the group R is preferably selected from the group R-G1 as defined hereinbefore.
  • group R is selected from the group R-G4 consisting of:
  • group R is selected from the group R-G6 consisting of
  • the group R 1 is preferably selected from the group R 1 -G1 as defined hereinbefore.
  • the group R 1 is selected from the group R 1 -G2 consisting of H, F, Cl, C 1-3 -alkyl, cyclopropyl, NC-, HO-, and C 1-3 -alkyl-O-, wherein each alkyl group or sub-group within the groups mentioned under R 1 -G2 is optionally substituted with 1 or more F atoms.
  • the group R 1 is selected from the group R 1 -G3 consisting of H, F, Cl, H 3 C-, H 3 C-H 2 C -, F 3 C-, NC-, and H 3 C-O-.
  • the group R 1 is selected from the group R 1 -G4 consisting of H 3 C-.
  • the group R 2 is preferably selected from the group R 2 -G1 as defined hereinbefore.
  • the group R 2 is selected from the group R 2 -G2 consisting of H, F, Cl, H 3 C-, F 3 C-, NC-, and H 3 CO-.
  • the group R 2 is selected from the group R 2 -G3 consisting of H and F.
  • the group R 2 is selected from the group R 2 -G4 consisting of H.
  • the group R 2 is selected from the group R 2 -G5 consisting of F.
  • the group R 3 is preferably selected from the group R 3 -G1 as defined hereinbefore.
  • the group R 3 is selected from the group R 3 -G2 consisting of of H, F, Cl, H 3 C-, NC-, and H 3 CO-.
  • the group R 3 is selected from the group R 3 -G3 consisting of H.
  • the group R N is preferably selected from the group R N -G1 as defined hereinbefore.
  • n is an integer selected from 1, 2, 3 and 4.
  • m is an integer selected from 1 and 2. More preferably, m is 2.
  • n is an integer selected from 1, 2 and 3.
  • n is an integer selected from 1 and 2. More preferably, n is 1.
  • Another embodiment concerns those compounds of formula I, wherein
  • R is selected from the group consisting of:
  • Another embodiment concerns those compounds of formula I, wherein
  • Another embodiment concerns those compounds of formula I, wherein
  • the compounds according to the invention and their intermediates may be obtained using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis for example using methods described in " Comprehensive Organic Transformations, 2nd edition”, Richard C. Larock, Wiley-VCH, 2009 ., and “ March's Advanced Organic Chemistry, 7th edition", Michael B. Smith, John Wiley & Sons, 2013 .
  • the compounds are obtained analogously to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section.
  • the sequence adopted in carrying out the reaction schemes may be varied. Variants of these reactions that are known to the skilled man but are not described in detail here may also be used.
  • the compounds of the invention I are preferably accessed from a precursor II that bears the carboxylic acid function in a protected or masked form as sketched in Scheme 1;
  • R, R 1 , R 2 , R 3 , m and n have the meanings as defined hereinbefore and hereinafter.
  • Suited precursor groups for the carboxylic acid may be, e.g., a carboxylic ester, a carboxylic amide, cyano, an olefin, oxazole, or a thiazole. All these groups have been transformed into the carboxylic acid function by different means which are described in the organic chemistry literature and are known to the one skilled in the art.
  • the preferred precursor group is a C 1-4 -alkyl or benzyl carboxylate, each of which may be additionally mono- or polysubstituted with fluorine, methyl, and/or methoxy.
  • ester groups may be hydrolyzed with an acid, such as hydrochloric acid or sulfuric acid, or an alkali metal hydroxide, such as lithium hydroxide, sodium hydroxide, or potassium hydroxide, to yield the carboxylic acid function; the hydrolysis is preferably conducted in aqueous solvents, such as water and tetrahydrofuran, 1,4-dioxane, alcohol, e.g., methanol, ethanol, and isopropanol, or dimethyl sulfoxide, at 0 to 120 °C.
  • aqueous solvents such as water and tetrahydrofuran, 1,4-dioxane, alcohol, e.g., methanol, ethanol, and isopropanol, or dimethyl
  • a tert -butyl ester is preferably cleaved under acidic conditions, e.g., trifluoroacetic acid or hydrochloric acid, in a solvent such as dichloromethane, 1,4-dioxane, isopropanol, or ethyl acetate.
  • a benzyl ester is advantageously cleaved using hydrogen in the presence of a transition metal, preferably palladium on carbon.
  • Benzyl esters bearing electron donating groups, such as methoxy, on the aromatic ring may also be removed under oxidative conditions; ceric ammonium nitrate (CAN) or 2,3-dichloro-5,6-dicyanoquinone (DDQ) are two commonly used reagents for this approach.
  • ceric ammonium nitrate CAN
  • DDQ 2,3-dichloro-5,6-dicyanoquinone
  • Compound II may be obtained from aminoindane III and pyridine IV which is decorated with the carboxylic acid precursor group and a leaving group (Scheme 2); R, R 1 , R 2 , R 3 , m and n in Scheme 2 have the meanings as defined hereinbefore and hereinafter.
  • the leaving group LG in IV is replaced with the NH group in III via a nucleophilic substitution reaction on the pyridine ring; suited LG may be F, Cl, Br, and I.
  • the reaction is usually carried out in the presence of a base, such as triethylamine, ethyldiisopropylamine, 1,8-diazabicyclo[5.4.0]undecene, carbonates, e.g., Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , and Cs 2 CO 3 , hydroxides, e.g., LiOH, NaOH, and KOH, alcoholates, e.g., NaOMe, NaOEt, and KO t Bu, and oxides, e.g., CaO and Ag 2 O.
  • a base such as triethylamine, ethyldiisopropylamine, 1,8-diazabicyclo[5.4.0]undecene
  • carbonates e.g., Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , and Cs 2 CO 3
  • hydroxides e.g., LiOH, NaOH, and KOH
  • Additives such as silver salts, e.g., AgNO 3 , AgOSO 2 CF 3 , and Ag 2 CO, may be beneficial for the reaction to proceed.
  • Preferred solvents are dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, acetonitrile, 1,4-dioxane, tetrahydrofuran, alcohol, e.g., ethanol or isopropanol, water, or mixtures thereof at temperatures of 20 to 220 °C.
  • a transition metal catalyst Preferably, coupling of aminoindane III and pyridine IV is mediated by a transition metal catalyst.
  • Suited pyridines IV for this proceeding bear Cl, Br, or I as LG and the catalyst may be derived from Cu, Ni, and Pd, preferably Pd.
  • the catalyst or the precursor thereof may be a complex of the transition metal with ligands such as phosphines, e.g.
  • tri- tert -butylphosphine tricyclohexyl-phosphine, 2-optionally substituted biphenyl-dicyclohexyl-phosphines, 2-optionally substituted biphenyl-di- tert -butylphosphines, 1,1'-bis(diphenylphosphino)ferrocene, triphenylphosphine, tritolylphosphine, or trifurylphosphine, phosphites, 1,3-disubstituted imidazole carbenes, 1,3-disubstituted imidazolidine carbenes, dibenzylideneacetone, allyl, or nitriles, an elemental form of the transition metal such as palladium on carbon or nanoparticles of palladium, or a salt of the transition metal such as fluoride, chloride, bromide, acetate, triflate, or trifluoroacetate that may be combined
  • the reaction is commonly conducted in the presence of a base such as an alcoholate, e.g., LiO t Bu, NaO t Bu, and KO t Bu, lithium hexamethyldisilazide, K 3 PO 4 , carbonate such as Cs 2 CO 3 , or phenolate such as sodium 2,6-di-tert-butyl-4-methyl-phenolate.
  • a base such as an alcoholate, e.g., LiO t Bu, NaO t Bu, and KO t Bu
  • lithium hexamethyldisilazide e.g., LiO t Bu, NaO t Bu, and KO t Bu
  • carbonate such as Cs 2 CO 3
  • phenolate such as sodium 2,6-di-tert-butyl-4-methyl-phenolate.
  • the coupling reactions are preferably conducted in benzene, toluene, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, alcohol such as t BuOH, water, or mixtures thereof, at temperatures in the range of 20 to 180 °C.
  • indanol V which, in turn, may be prepared from indanone VI (Scheme 3); R, R 1 , R 2 , m and n in Scheme 3 have the meanings as defined hereinbefore and hereinafter.
  • the reduction of the keto group in compound VI is a standard transformation in organic synthesis which may be accomplished with lithium borohydride, sodium borohydride, lithium aluminum hydride, or diisobutylaluminum hydride.
  • the other reducing agents mentioned are preferably used in inert solvents, such as tetrahydrofuran, diethyl ether, dichloromethane, and toluene, at -80 to 60 °C.
  • the reduction of the keto group may also be conducted in a stereoselective fashion providing the alcohol in enantiomerically enriched or pure form.
  • Suited chiral reducing agents are boranes combined with an enantiomerically pure [1,3,2]oxazaborol (Corey-Bakshi-Shibata reaction or Corey-Itsuno reaction) or formic acid, formates, hydrogen, or silanes in the presence of an enantiomerically pure transition metal catalyst.
  • Typical reaction conditions for the former approach comprise borane (complexed with, e.g., dimethyl sulfide) and (R)- or (S)-3,3-diphenyl-1-methyltetrahydro-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborol in, e.g., dichloromethane, toluene, methanol, tetrahydrofuran, or mixtures thereof, at 0 to 60 °C.
  • a chiral transition metal catalyst such as a ruthenium complex, e.g., chloro ⁇ [(1S,2S)-(-)-2-amino-1,2-diphenylethyl](4-toluenesulfonyl)-amido ⁇ -(mesitylene)ruthenium(II)
  • a chiral transition metal catalyst such as a ruthenium complex, e.g., chloro ⁇ [(1S,2S)-(-)-2-amino-1,2-diphenylethyl](4-toluenesulfonyl)-amido ⁇ -(mesitylene)ruthenium(II)
  • a base e.g., triethylamine, in dichloromethane
  • the OH group in compound V may be replaced with NH 2 following a two-step procedure via a protected, e.g., as phthalimide, or masked, e.g., as azide, amino derivative.
  • Phthalimide can be introduced employing the conditions of the Mitsunobu reaction. The transformation is routinely conducted with phthalimide, a phosphine, and an azodicarboxylic ester or amide in tetrahydrofuran, 1,4-dioxane, diethyl ether, toluene, benzene, dichloromethane, or mixtures thereof, at -30 to 100 °C.
  • Phosphines commonly used are triphenylphosphine and tributylphosphine which are regularly combined with dimethyl azodicarboxylate, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-(4-chlorobenzyl) azodicarboxylate, dibenzyl azodicarboxylate, di-tert-butyl azodicarboxylate, azodicarboxylic acid bis-(dimethylamide), azodicarboxylic acid dipiperidide, or azodicarboxylic acid dimorpholide.
  • the amino group may be liberated from phthalimide using hydrazine in ethanol, ethylene-1,2-diamine in n -butanol, or 1-butylamine in n -butanol.
  • the azide group can be introduced from the hydroxy precursor V employing hydrazoic acid or phosphoryl azide and the conditions of the Mitsunobu reaction as described above or variants thereof.
  • Phosphoryl azide combined with a base, such as 1,8-diazabicyclo[5.4.0]undecene, may also accomplish the transformation in tetrahydrofuran or toluene at -10 to 60°C.
  • the azide is transformed into the amino function using, e.g., hydrogen in the presence of a transition metal such as palladium on carbon. Both proceedings may give the aminoindane III in enantiomerically pure form when starting from the isomerically pure precursor V.
  • Suitable reagents for this transformation include diazomethane in the presence of a transition metal catalyst such as palladium diacetate (see, e.g., WO2011/94890 ), trimethyloxosulfonium halide in the presence of a base such as sodium hydride (see, e.g., WO2005/103032 ), and diiodomethane in the presence of copper and zinc (see, e.g., US628476 ).
  • a transition metal catalyst such as palladium diacetate
  • a base such as sodium hydride
  • diiodomethane in the presence of copper and zinc
  • pyridine IV' is obtained from vinylpyridine VIII and diazoacetic ester IX in the presence of a transition metal catalyst.
  • Suitable catalyst systems for this transformation include, for example, palladium diacetate (see, e.g., WO2007/104717 ), cobalt(II) porphyrins (see, e.g., WO2006/103503 ), rhodium complexes (see, e.g., WO2006/87169 ), and copper complexes (see, e.g., WO2010/51819 ).
  • Mixtures of cis- and trans -cyclopropyl esters are generally formed with the trans-system predominant and the ratio depending on the catalyst system and substrates used. Enantioselective reactions of this type are reported using chiral transition metal catalysts derived from copper and cobalt (see, e.g., J. Am. Chem Soc. 1991, 113, 726-728 ) and variations thereof.
  • protecting groups For example, potentially reactive groups present, such as hydroxy, carbonyl, carboxy, amino, alkylamino, or imino, may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
  • Suitable protecting groups for the respective functionalities and their removal are well known to the one skilled in the art and are described in the literature of organic synthesis for example in " Protecting Groups, 3rd Edition", Philip J. Kocienski, Theime, 2005 or " Greene's Protective Groups in Organic Synthesis, 4th Edition", Peter G. M. Wuts, Theadora W. Greene, John Wiley and Sons, 2007 .
  • the compounds of general formula I may be resolved into their enantiomers and/or diastereomers as mentioned below.
  • cis / trans mixtures may be resolved into their cis and trans isomers and racemic compounds may be separated into their enantiomers.
  • the cis / trans mixtures may be resolved, for example, by chromatography into the cis and trans isomers thereof.
  • the compounds of general formula I which occur as racemates may be separated by methods known per se into their optical antipodes and diastereomeric mixtures of compounds of general formula I may be resolved into their diastereomers by taking advantage of their different physico-chemical properties using methods known per se, e.g. chromatography and/or fractional crystallization; if the compounds obtained thereafter are racemates, they may be resolved into the enantiomers as mentioned below.
  • racemates are preferably resolved by column chromatography on chiral phases or by crystallization from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as esters or amides with the racemic compound.
  • Salts may be formed with enantiomerically pure acids for basic compounds and with enantiomerically pure bases for acidic compounds.
  • Diastereomeric derivatives are formed with enantiomerically pure auxiliary compounds, e.g. acids, their activated derivatives, or alcohols. Separation of the diastereomeric mixture of salts or derivatives thus obtained may be achieved by taking advantage of their different physico-chemical properties, e.g.
  • the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • Optically active acids commonly used for such a purpose as well as optically active alcohols applicable as auxiliary residues are known to those skilled in the art.
  • the compounds of formula I may be converted into salts, particularly for pharmaceutical use into the pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • compound(s) according to this invention denote the compounds of the formula (I) according to the present invention including their tautomers, stereoisomers and mixtures thereof and the salts thereof, in particular the pharmaceutically acceptable salts thereof, and the solvates and hydrates of such compounds, including the solvates and hydrates of such tautomers, stereoisomers and salts thereof.
  • treatment embrace both preventative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment.
  • treatment and “treating” comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form.
  • Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease.
  • compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.
  • treatment and “treating” comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
  • this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in particular humans.
  • terapéuticaally effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.
  • modulated or “modulating”, or “modulate(s)", as used herein, unless otherwise indicated, refer to the activation of the G-protein-coupled receptor GPR40 with one or more compounds of the present invention.
  • mediated refers to the (i) treatment, including prevention of the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.
  • substituted means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound.
  • C 1-6 -alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
  • the last named subgroup is the radical attachment point, for example, the substituent "aryl-C 1-3 -alkyl-" means an aryl group which is bound to a C 1-3 -alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
  • An asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
  • the numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
  • the term "3-carboxypropyl-group” represents the following substituent: wherein the carboxy group is attached to the third carbon atom of the propyl group.
  • the terms "1-methylpropyl-", “2,2-dimethylpropyl-” or "cyclopropylmethyl-” group represent the following groups:
  • the asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
  • each X, Y and Z group is optionally substituted with
  • each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined.
  • R ex denotes H, C 1-3 -alkyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkyl-C 1-3 -alkyl or C 1-3 -alkyl-O-, wherein each alkyl group is optionally substituted with one or more L ex .” or the like means that in each of the beforementioned groups which comprise the term alkyl, i.e. in each of the groups C 1-3 -alkyl, C 3-6 -cycloalkyl-C 1-3 -alkyl and C 1-3 -alkyl-O-, the alkyl moiety may be substituted with L ex as defined.
  • a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc%) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention e.g. trifluoro acetate salts
  • Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
  • halogen generally denotes fluorine, chlorine, bromine and iodine.
  • C 1-n -alkyl wherein n is an integer from 1 to n, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms.
  • C 1-5 -alkyl embraces the radicals H 3 C-, H 3 C-CH 2 -, H 3 C-CH 2 -CH 2 -, H 3 C-CH(CH 3 )-, H 3 C-CH 2 -CH 2 -CH 2 -, H 3 C-CH 2 -CH(CH 3 )-, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-C(CH 3 ) 2 -, H 3 C-CH 2 -CH 2 -CH 2 -CH 2 -, H 3 C-CH 2 -CH 2 -CH(CH 3 )-, H 3 C-CH 2 -CH(CH 3 )-CH 2 -, H 3 C-CH(CH 3 )-CH 2 -, H 3
  • C 1-n -alkylene wherein n is an integer 1 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms.
  • C 1-4 -alkylene includes -(CH 2 )-, -(CH 2 -CH 2 )-, -(CH(CH 3 ))-, -(CH 2 -CH 2 -CH 2 )-, -(C(CH 3 ) 2 )-,-(CH(CH 2 CH 3 ))-, -(CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 ))-, -(CH 2 -CH 2 -CH 2 -CH 2 )-, -(CH 2 -CH 2 -CH(CH 3 ))-, -(CH(CH 3 )-CH 2 -CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -C(CH 3 ) 2
  • C 2-n -alkenyl is used for a group as defined in the definition for "C 1-n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
  • C 2-n -alkynyl is used for a group as defined in the definition for "C 1-n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
  • C 2-3 -alkynyl includes -C ⁇ CH, -C ⁇ C-CH 3 , -CH 2 -C ⁇ CH.
  • C 3-n -cycloalkyl wherein n is an integer 4 to n, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms.
  • the cyclic group may be mono-, bi-, tri- or spirocyclic, most preferably monocyclic.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1.]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.
  • the assay is started by substitution of the culture medium by stimulation buffer (Hepes 10 mM, CaCl 2 1 mM, MgCl 2 0.5 mM, KCI 4.2 mM, NaCl 146 mM, glucose 5.5 mM and LiCI 50 mM, pH 7.4).
  • Cells are stimulated for 1 h at 37 °C, 5% CO 2 by addition of the compounds that are diluted in stimulation buffer containing LiCI.
  • Assays are stopped by adding HTRF-conjugates (IP1-d2 and Anti-IP1 cryptate Tb) and lysis buffer, provided by the manufacturer. After an incubation time of 1 h at room temperature plates are measured using an EnVisionTM, Perkin Elmer.
  • the obtained fluorescence ratios at 665/615 nM are then used to calculate the pEC 50 values using Assay Explorer 3.3 Software (Accelrys, Inc.) by interpolation using an IP 1 reference curve and subsequent sigmoidal curve fitting allowing for a variable hill slope.
  • the compounds according to the invention typically have EC 50 values in the range from about 1 nM to about 10 ⁇ M, preferably less than 1 ⁇ M, more preferably less than 100 nM.
  • EC 50 values for compounds according to the invention are shown in the following table. The number of the compound corresponds to the number of the Example in the experimental section. Table 2: Example EC 50 [nM] Example EC 50 [nM] Example EC 50 [nM] Example EC 50 [nM] Example EC 50 [nM] 1 7 2 11 3 4 4 8 5 16 6 19 7 19 8 16 9 259 10 497 12 568 13 27 14 4 15 18 16 11 17 13 19 16 20 18 21 60 22 27 23 5 24 318 25 177 26 4 28 71 29 17 31 31 32 35 33 14 34 4130 35 23 36 6 37 11 40 940 41 33 44 4130 45 5 46 629 47 26 48 427 50 13 51 7 53 13 55 208 56 151 57 107 58 462 60 61 61 5 63 20 64 29 66 39 71 6 72 6 73 17 74 49 75 186 76 3 77 20 79 23 80 22 81 8 82 18 83 8 84 212 85 91 86 174
  • Degradation kinetics is used to simulate chemical stability of compounds in the acidic part of the gastro intestinal tract.
  • the compounds of the invention show superior chemical stability in acidic aqueous media (pH value ca. 1.2) compared to the bulk of compounds explicitly disclosed in WO 2013/178575 .
  • Their application as medical drugs to treat human diseases is therefore less restricted and troublesome.
  • the chemical stability of the compounds of the invention at pH value of ca. 1.2 is determined as follows: Compound is dissolved in an HPLC vial either in a mixture of acetonitrile/0.1 M aqueous HCI (2:3; pH ca. 1.2) or in a mixture of acetonitrile/McIlvaine buffer pH 7.4 (2:3) to get a concentration of approximately 0.25 mg/ml. The vial was then transferred into an HPLC autosampler system and maintained at a temperature of 37 °C. A first sample is taken and injected immediately into a standard HPLC system with a UV DAD detector. Further samples are injected after 2, 4, 6, 8 and 10 hours.
  • the amount of degraded compound according to the invention after 2 h at pH value of ca. 1.2 determined as described above is typically significantly below 1.5%, mostly below 0.5%.
  • Example in this invention Amount of degradation after 2 h
  • Example in WO 2013/178575 Amount of degradation after 2 h 1 ⁇ 0.5% 11 5% 2 ⁇ 0.5% 15 3% 33 8% 4 ⁇ 0.5% 17 8% 54 2.5% 19 ⁇ 1.0% 20 ⁇ 0.5% 21 ⁇ 0.5% 23 ⁇ 0.5% 26 ⁇ 0.5% 31 ⁇ 0.5% 35 ⁇ 0.5% 36 ⁇ 0.5% 41 ⁇ 1.5% 46 ⁇ 0.5% 47 ⁇ 0.5% 50 ⁇ 1.0% 56 ⁇ 0.5% 58 ⁇ 0.5% 63 ⁇ 0.5% 66 ⁇ 1.0% 72 ⁇ 0.5% 74 ⁇ 1.0% 75 ⁇ 0.5%
  • the aqueous solubility of the compounds of the invention is determined by comparing the amount dissolved in buffer to the amount in an acetonitrile/water (1/1) solution. Starting from a 10 mM DMSO stock solution aliquots are diluted with acetonitrile/water (1/1) or buffer, respectively. After 24 h of shaking, the solutions are filtrated and analyzed by LC-UV. The amount dissolved in buffer is compared to the amount in the acetonitrile solution.
  • Solubility is usually being measured from 0.001 to 0.125 mg/mL at a DMSO concentration of 2.5%. If more than 90% of the compound is dissolved in buffer, the value is marked with ">".
  • the compounds of the invention show higher solubility at low pH value (pH 2.2, emulating the acidic part of the gastro intestinal tract) compared with the bulk of compounds explicitly disclosed in WO 2013/178575 . Their development and application is therefore more convenient and reliable.
  • the following table presents the data for selected compounds of this invention and compounds from WO 2013/178575 (for structures see above below Table 3).
  • the inhibition of cytochrome P450 2C8-isoenzyme catalyzed deethylation of amodiaquine by the test compound is assayed at 37 °C with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl 2 (5 mM), human liver microsomes (0.05 mg/mL), amodiaquine (1 ⁇ M) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 ⁇ M with subsequent serial 1:4 dilutions).
  • the IC 50 is assigned " ⁇ lowest concentration tested” (usually ⁇ 0.4 ⁇ M). If the inhibition of the reaction is still ⁇ 50% at the highest concentration of the test compound, the IC 50 is assigned "> highest concentration tested" (usually >50 ⁇ M).
  • the compounds of the invention show lower inhibition of the cytochrome P450 2C8-isoenzyme compared with the bulk of compounds explicitly disclosed in WO 2013/178575 . Their potential for causing unwanted side-effects is therefore decreased.
  • the following table displays the data for selected compounds of this invention and compounds from WO 2013/178575 (for structures see above below Table 3).
  • IC 50 Example in WO 2013/178575 IC 50 [ ⁇ M] [ ⁇ M] 1 16 11 12 2 30 15 10 3 19 45 5 4 46 17 6 5 12 33 5 6 >50 54 9 7 38 8 >50 13 49 14 45 15 26 16 46 17 34 19 26 20 24 21 >50 22 >50 23 11 24 >50 25 4 26 35 28 >50 29 >50 31 32 12 33 26 34 >50 35 18 36 10 37 17 40 >50 41 34 44 >50 45 24 46 32 47 12 48 >50 50 21 51 12 53 11 55 >50 56 33 57 19 58 >50 59 >50 60 25 61 15 63 >50 64 >50 66 >50 71 18 72 8 73 20 74 21 75 >50 76 30
  • the inhibition of cytochrome P450 2C9-isoenzyme catalyzed hydroxylation of diclofenac by the test compound is assayed at 37 °C with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl 2 (5 mM), human liver microsomes (0.1 mg/mL), diclofenac (10 ⁇ M) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g., highest concentration 10-50 ⁇ M with subsequent serial 1:4 dilutions).
  • the IC 50 is assigned " ⁇ lowest concentration tested” (usually ⁇ 0.4 ⁇ M). If the inhibition of the reaction is still ⁇ 50% at the highest concentration of the test compound, the IC 50 is assigned "> highest concentration tested" (usually >50 ⁇ M).
  • the compounds of the invention show lower inhibition of the cytochrome P450 2C9-isoenzyme compared with the bulk of compounds explicitly disclosed in WO 2013/178575 . Their potential for causing unwanted side-effects is therefore decreased.
  • the following table displays the data for selected compounds of this invention and compounds from WO 2013/178575 (for structures see above below Table 3).
  • IC 50 Example in WO 2013/178575 IC 50 [ ⁇ M] [ ⁇ M] 1 48 11 17 2 >50 15 31 3 >50 45 10 4 >50 17 14 5 48 33 7 6 >50 54 10 7 >50 8 >50 13 >50 14 >50 15 >50 16 >50 17 36 19 35 20 33 21 >50 22 >50 23 15 24 >50 25 >50 26 >50 28 >50 29 >50 31 27 32 24 33 >50 34 >50 35 34 36 >50 37 >50 40 >50 41 >50 44 >50 45 >50 46 9 47 14 48 >50 50 22 51 17 53 14 55 >50 56 28 57 48 58 >50 59 34 60 9 61 33 63 >50 64 >50 66 >50 71 >50 72 18 73 45 74 14 75 >50 76 40
  • the compounds of general formula I according to the invention are theoretically suitable for the treatment of all those diseases or conditions which may be affected or which are mediated by the activation of the G-protein-coupled receptor GPR40.
  • the present invention relates to a compound of general formula I as a medicament.
  • a compound of general formula I or a pharmaceutical composition according to this invention for the treatment and/or prevention of diseases or conditions which are mediated by the activation of the G-protein-coupled receptor GPR40 in a patient, preferably in a human.
  • the present description relates to a method for treating a disease or condition mediated by the activation of the G-protein-coupled receptor GPR40 in a mammal that includes the step of administering to a patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention.
  • the compounds and pharmaceutical compositions of the present invention are particularly suitable for treating diabetes mellitus, in particular Type 2 diabetes, Type 1 diabetes, complications of diabetes (such as e.g. retinopathy, nephropathy or neuropathies, diabetic foot, ulcers or macroangiopathies), metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia.
  • diabetes mellitus in particular Type 2 diabetes, Type 1 diabetes, complications of diabetes (such as e.g. retinopathy, nephropathy or neuropathies, diabetic foot, ulcers or macroangiopathies), metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure
  • the compounds and pharmaceutical compositions of the present invention are also suitable for preventing beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta cells.
  • the compounds and pharmaceutical compositions of the present invention are also suitable for improving or restoring the functionality of pancreatic cells, and also for increasing the number and size of pancreatic beta cells.
  • the invention relates to compounds of formula I and pharmaceutical compositions according to the invention for use in preventing, delaying, slowing the progression of and/or treating metabolic diseases, particularly in improving the glycaemic control and/or beta cell function in the patient.
  • the invention relates to compounds of formula I and pharmaceutical compositions according to the invention for use in preventing, delaying, slowing the progression of and/or treating type 2 diabetes, overweight, obesity, complications of diabetes and associated pathological conditions.
  • compositions according to the invention are suitable for use in one or more of the following therapeutic processes:
  • the compounds and pharmaceutical compositions according to the invention are suitable for the treatment of obesity, diabetes (comprising type 1 and type 2 diabetes, preferably type 2 diabetes mellitus) and/or complications of diabetes (such as for example retinopathy, nephropathy or neuropathies, diabetic foot, ulcers or macroangiopathies).
  • diabetes comprising type 1 and type 2 diabetes, preferably type 2 diabetes mellitus
  • complications of diabetes such as for example retinopathy, nephropathy or neuropathies, diabetic foot, ulcers or macroangiopathies.
  • the compounds according to the invention are most particularly suitable for treating type 2 diabetes mellitus.
  • the dose range of the compounds of general formula I applicable per day is usually from 0.001 to 10 mg per kg body weight, for example from 0.01 to 8 mg per kg body weight of the patient.
  • Each dosage unit may conveniently contain from 0.1 to 1000 mg, for example 0.5 to 500 mg.
  • the actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the compound or composition will be administered at dosages and in a manner which allows a therapeutically effective amount to be delivered based upon patient's unique condition.
  • compositions, including any combinations with one or more additional therapeutic agents, according to the invention may be administered by oral, transdermal, inhalative, parenteral or sublingual route.
  • oral or intravenous administration is preferred.
  • Suitable preparations for administering the compounds of formula I will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc. Oral formulations, particularly solid forms such as e.g. tablets or capsules are preferred.
  • the content of the pharmaceutically active compound(s) is advantageously in the range from 0.1 to 90 wt.-%, for example from 1 to 70 wt.-% of the composition as a whole.
  • Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula I with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
  • excipients for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
  • the tablets may also consist of several layers.
  • the particular excipients, carriers and/or diluents that are suitable for the desired preparations will be familiar to the skilled man on the basis of his specialist knowledge.
  • the preferred ones are those that are suitable for the particular formulation and method of administration that are desired.
  • preparations or formulations according to the invention may be prepared using methods known per se that are familiar to the skilled man, such as for example by mixing or combining at least one compound of formula I according to the invention, or a pharmaceutically acceptable salt of such a compound, and one or more excipients, carriers and/or diluents.
  • the compounds of the invention may further be combined with one or more, preferably one additional therapeutic agent.
  • the additional therapeutic agent is selected from the group of therapeutic agents useful in the treatment of diseases or conditions described hereinbefore, in particular associated with metabolic diseases or conditions such as for example diabetes mellitus, obesity, diabetic complications, hypertension, hyperlipidemia.
  • Additional therapeutic agents which are suitable for such combinations include in particular those which for example potentiate the therapeutic effect of one or more active substances with respect to one of the indications mentioned and/or which allow the dosage of one or more active substances to be reduced.
  • a compound of the invention may be combined with one or more additional therapeutic agents selected from the group consisting of antidiabetic agents, agents for the treatment of overweight and/or obesity and agents for the treatment of high blood pressure, heart failure and/or atherosclerosis.
  • Antidiabetic agents are for example metformin, sulphonylureas, nateglinide, repaglinide, thiazolidinediones, PPAR-(alpha, gamma or alpha/gamma) agonists or modulators, alpha-glucosidase inhibitors, DPPIV inhibitors, SGLT2-inhibitors, insulin and insulin analogues, GLP-1 and GLP-1 analogues or amylin and amylin analogues, cycloset, 11 ⁇ -HSD inhibitors.
  • Other suitable combination partners are inhibitors of protein tyrosinephosphatase 1, substances that affect deregulated glucose production in the liver, such as e.g.
  • glucose-6-phosphatase or fructose-1,6-bisphosphatase
  • glycogen phosphorylase glycogen phosphorylase
  • glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, alpha2-antagonists, CCR-2 antagonists or glucokinase activators.
  • One or more lipid lowering agents are also suitable as combination partners, such as for example HMG-CoA-reductase inhibitors, fibrates, nicotinic acid and the derivatives thereof, PPAR-(alpha, gamma or alpha/gamma) agonists or modulators, PPAR-delta agonists, ACAT inhibitors or cholesterol absorption inhibitors such as, bile acid-binding substances such as, inhibitors of ileac bile acid transport, MTP inhibitors, or HDL-raising compounds such as CETP inhibitors or ABC1 regulators.
  • HMG-CoA-reductase inhibitors such as for example HMG-CoA-reductase inhibitors, fibrates, nicotinic acid and the derivatives thereof, PPAR-(alpha, gamma or alpha/gamma) agonists or modulators, PPAR-delta agonists, ACAT inhibitors or cholesterol absorption inhibitors such as, bile acid-binding substances such
  • Therapeutic agents for the treatment of overweight and/or obesity are for example antagonists of the cannabinoid1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists, ⁇ 3-agonists, leptin or leptin mimetics, agonists of the 5HT2c receptor.
  • Therapeutic agents for the treatment of high blood pressure, chronic heart failure and/or atherosclerosis are for example A-II antagonists or ACE inhibitors, ECE inhibitors, diuretics, ⁇ -blockers, Ca-antagonists, centrally acting antihypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable.
  • Angiotensin II receptor antagonists are preferably used for the treatment or prevention of high blood pressure and complications of diabetes, often combined with a diuretic such as hydrochlorothiazide.
  • the dosage for the combination partners mentioned above is usually 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dose.
  • compounds of the present invention and/or pharmaceutical compositions comprising a compound of the present invention optionally in combination with one or more additional therapeutic agents are administered in conjunction with exercise and/or a diet.
  • a compound according to the invention in combination with one or more additional therapeutic agents described hereinbefore and hereinafter for the treatment of diseases or conditions which may be affected or which are mediated by the activation of the G-protein-coupled receptor GPR40, in particular diseases or conditions as described hereinbefore and hereinafter.
  • the present description relates a method for treating a disease or condition mediated by the activation of the G-protein-coupled receptor GPR40 in a patient that includes the step of administering to the patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of one or more additional therapeutic agents described in hereinbefore and hereinafter,
  • the compound according to the invention and the one or more additional therapeutic agents may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so-called kit-of-parts.
  • this invention relates to a pharmaceutical composition which comprises a compound according to the invention and one or more additional therapeutic agents described hereinbefore and hereinafter, optionally together with one or more inert carriers and/or diluents.
  • ambient temperature and “room temperature” are used interchangeably and designate a temperature of about 20 °C.
  • 1 H-NMR and/or mass spectra have been obtained for the compounds prepared.
  • Intermediates and Examples reported in the following bearing a basic or acidic group may be obtained as a corresponding salt or neutral compound depending on the purification method and conditions employed. Salts can be transformed into their neutral counterparts by standard procedures known to the one skilled in the art.
  • Aqueous 2 M Na 2 CO 3 solution (50 mL) is added to a flask charged with a stir bar, 2-chloro-5-iodo-pyridine (10.0 g), vinyl boronic acid pinacol ester (7.9 mL), and 1,4-dioxane (100 mL) at room temperature.
  • the mixture is purged with Ar for 5 min prior to the addition of 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (1.0 g).
  • the title compound is prepared from 2-chloro-pyridine-5-carbaldehyde as described in EP1236723 .
  • Step 2 trans- 2-(6-Chloro-pyridin-3-yl)-cyclopropanecarboxylic acid ethyl ester 5,10,15,20-Tetraphenyl-21H,23H-porphine cobalt(II) (0.5 g), 1-methylimidazole (7.8 g), and ethyl diazoacetate (13% in dichloromethane; 31 mL) are added to a flask charged with a stir bar, 2-chloro-5-vinyl-pyridine (4.4 g), and toluene (50 mL) at room temperature. The mixture is stirred at room temperature for 5 min and then at 80 °C overnight.
  • the title compound is obtained from 3-(6-chloro-pyridin-3-yl)-acrylic acid ethyl ester and trimethylsulfoxonium halide as described in EP1741708 .
  • the racemic mixture is resolved via crystallization of the diastereomeric salts formed upon treatment of the corresponding racemic mixture of carboxylic acids with ( R )- or ( S )-1-phenethylamine in, e.g., an alcohol such as isopropanol.
  • the carboxylic acids of the 1-phenethylammonium salts are liberated and separated by treatment with hydrochloric acid solution and extraction with ethyl acetate.
  • Step 1 ( S )-4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-ol
  • Step 2 ( S )-4-[2,6-Dimethyl-4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-indan-1-ol
  • Step 3 2- ⁇ ( R )-4-[2,6-Dimethyl-4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-indan-1-yl ⁇ -isoindole-1,3-dione
  • Step 4 ( R )-4-[2,6-Dimethyl-4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-indan-1-ylamine
  • Step 1 ( S )-4-[4-(3-Hydroxy-3-methyl-butoxy)-2,6-dimethyl-phenyl]-indan-1-ol
  • Step 2 2- ⁇ ( R )-4-[4-(3-Hydroxy-3-methyl-butoxy)-2,6-dimethyl-phenyl]-indan-1-yl ⁇ -isoindole-1,3-dione
  • Step 3 4-[4-(( R )-1-Amino-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol
  • Step 1 ( S )-4-[2,6-Dimethyl-4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-7-fluoro-indan-1-ol
  • Step 2 5-[4-(( R )-1-Azido-7-fluoro-indan-4-yl)-3,5-dimethyl-phenyl]-2-methyl-2H-tetrazole
  • Step 3 ( R )-4-[2,6-Dimethyl-4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-7-fluoro-indan-1-ylamine
  • Step 1 ( S )-7-Fluoro-4-[4-(3-hydroxy-3-methyl-butoxy)-2,6-dimethyl-phenyl]-indan-1-ol
  • Step 2 4-[4-(( R )-1-Azido-7-fluoro-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol
  • Step 3 4-[4-(( R )-1-Amino-7-fluoro-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol
  • Step 1 4-Trimethylsilyl-indan-1-one
  • Step 2 ( S )-4-Trimethylsilanyl-indan-1-ol
  • Formic acid (0.22 mL) is added to a solution of triethylamine (0.70 mL) in dichloromethane (4 mL) chilled in an ice bath.
  • 4-Trimethylsilyl-indan-1-one (0.34 g) is added and the solution is warmed to room temperature.
  • the flask is purged with argon for 5 min prior to the addition of chloro ⁇ [(1 S ,2 S )-(-)-2-amino-1,2-diphenylethyl](4-toluenesulfonyl)amido ⁇ -(mesitylene)ruthenium(II) (52 mg).
  • the mixture is stirred at room temperature overnight.
  • Step 3 2-(( R )-4-Trimethylsilyl-indan-1-yl)-isoindole-1,3-dione
  • Step 4 ( R )-4-Trimethylsilyl-indan-1-ylamine
  • Step 1 ( S )-7-Fluoro-4-trimethylsilyl-indan-1-ol
  • n-Butyl lithium (1.6 mol/L in hexanes; 60 mL) is added dropwise to a flask charged with a stir bar, ( S )-4-bromo-7-fluoro-indan-1-ol (10.0 g), and tetrahydrofuran (80 mL) cooled to -75 °C.
  • the mixture is stirred below -70 °C for 45 min prior to the addition of chlorotrimethylsilane (12 mL).
  • the mixture is warmed to room temperature overnight.
  • the mixture is cooled to -50 °C, treated with 4 M aqueous HCI solution (25 mL), and warmed to room temperature.
  • Step 2 (( R )-1-Azido-7-fluoro-indan-4-yl)-trimethyl-silane
  • Step 3 ( R )-7-Fluoro-4-trimethylsilyl-indan-1-ylamine
  • Step 1 (1 S ,2 S )-2-[6-(( R )-7-Fluoro-4-trimethylsilyl-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid
  • Step 2 (1 S ,2 S )-2-[6-(( R )-7-Fluoro-4-trimethylsilyl-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid methyl ester
  • lodomethane (0.38 mL) is added to a mixture of (1 S ,2 S )-2-[6-(( R )-7-fluoro-4-trimethylsilyl-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid (2.15 g), K 2 CO 3 (1.00 g), and N,N-dimethylformamide (10 mL) at room temperature. The mixture is stirred at room temperature overnight. Water is added and the resulting mixture is extracted with ethyl acetate. The combined extract is dried (Na 2 SO 4 ) and concentrated.
  • Step 3 (1 S ,2 S )-2-[6-(( R )-7-Fluoro-4-iodo-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid methyl ester
  • Iodine monochloride (1 M in dichloromethane; 3.5 mL) is added to (1 S ,2 S )-2-[6-(( R )-7-fluoro-4-trimethylsilyl-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid methyl ester (1.28 g) in dichloromethane (10 mL) chilled in an ice bath. The solution is warmed to room temperature overnight. Aqueous NaHCO 3 solution is added and the resulting mixture is extracted with dichloromethane. The combined extract is dried (Na 2 SO 4 ) and concentrated.
  • Step 4 (1 S ,2 S )-2- ⁇ 6-[( R )-7-Fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-ylamino]-pyridin-3-yl ⁇ -cyclopropanecarboxylic acid methyl ester
  • Step 1 (1 S ,2 S )-2-[6-(( R )-4-Trimethylsilyl-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid
  • Step 2 (1 S ,2 S )-2-[6-(( R )-4-Trimethylsilyl-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid methyl ester
  • Step 3 (1 S ,2 S )-2-[6-(( R )-4-Iodo-indan-1-ylamino)-pyridin-3-yl]-cyclopropanecarboxylic acid methyl ester
  • Step 4 (1 S ,2 S )-2- ⁇ 6-[( R )-4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-ylamino]-pyridin-3-yl ⁇ -cyclopropanecarboxylic acid methyl ester
  • a vial is charged with a stir bar, ( R )-4-[2,6-dimethyl-4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-indan-1-ylamine (0.35 g), (1 S ,2 S )-2-(6-chloro-pyridin-3-yl)-cyclopropane-carboxylic acid ethyl ester (0.30 g), sodium tert -butoxide (44 mg), and 1,4-dioxane (3 mL) at room temperature.
  • the vial is purged with Ar for 10 min prior to the addition of chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) (BRETTPHOS Pd G1 methyl- tert -butyl ether adduct; 44 mg).
  • the vial is sealed and the mixture is stirred in a microwave oven at 100 °C for 30 min. After cooling to room temperature, aqueous NaOH solution (10 M, 2 mL) is added and the mixture is stirred at 40 °C overnight.
  • the title compound is prepared from (1 S ,2 S )-2-(6-chloro-pyridin-3-yl)-cyclopropane-carboxylic acid ethyl ester and 4-[4-(( R )-1-amino-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol following a procedure analogous to that described for Example 1.
  • the title compound is prepared from (1 S ,2 S )-2-(6-chloro-pyridin-3-yl)-cyclopropane-carboxylic acid ethyl ester and 4-[4-(( R )-1-amino-7-fluoro-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol following a procedure analogous to that described for Example 1.
  • the title compound is prepared from trans -2-(6-chloro-pyridin-3-yl)-cyclopropane-carboxylic acid ethyl ester (racemate) and 4-[4-(( R )-1-amino-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol following a procedure analogous to that described for Example 1.
  • the title compound is prepared from trans -2-(6-chloro-pyridin-3-yl)-cyclopropane-carboxylic acid ethyl ester (racemate) and 4-[4-(( R )-1-amino-7-fluoro-indan-4-yl)-3,5-dimethyl-phenoxy]-2-methyl-butan-2-ol following a procedure analogous to that described for Example 1.
  • the title compound is obtained from the diastereomeric mixture (Example 5) upon SFC separation on chiral phase (column: IC (Daicel Corp.), 5 ⁇ m, 250 mm x 10 mm; eluent: scCO 2 /isopropanol+20 mM NH 3 60:40, 40 °C, 120 bar, 10 mL/min).
  • the title compound is obtained from the diastereomeric mixture (Example 7) upon SFC separation on chiral phase (column: Chiralcel AD-H (Daicel Corp.), 5 ⁇ m, 250 mm x 20 mm; eluent: scCO 2 /isopropanol+20 mM NH 3 65:35, 40 °C, 150 bar, 60 mL/min).
  • the following compounds compiled in the table may be obtained from (1 S ,2 S )-2- ⁇ 6-[( R )-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-ylamino]-pyridin-3-yl ⁇ -cyclopropane-carboxylic acid methyl ester or (1 S ,2 S )-2- ⁇ 6-[( R )-7-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-ylamino]-pyridin-3-yl ⁇ -cyclopropanecarboxylic acid methyl ester and the bromide of the respective coupling partner following the principal procedure described in Step 2 of Intermediate 4 accompanied or followed by hydrolysis of the resulting methyl ester group.
  • the coupling product obtained as described immediately above is taken up in methanol (1 mL) and tetrahydrofuran (1 mL) and treated with aqueous 4 M NaOH solution (0.1 mL, ca. 20 eq.) at room temperature overnight.
  • the mixture is acidified with trifluoroacetic acid and chromatographed (HPLC on reversed phase, acetonitrile/water/trifluoroacetic acid) to give the corresponding carboxylic acid as trifluoroacetic acid salt.
  • the crude product may also be purified under basic HPLC conditions employing ammonia as additive.
  • the free product is obtained from the salt upon treatment of the dissolved salt with pH adjusted aqueous solution according to standard procedures.
  • the transition metal catalyzed coupling and the saponification of the resulting ester are carried out in the same reaction vessel without work-up in between by adding the aqueous base to the mixture of the coupling reaction after complete consumption of the boronic ester at room temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

  1. Composé de formule (I)
    Figure imgb0155
     dans laquelle
    R est sélectionné dans le groupe consistant en
    H, F, Cl, Br, I, C1-6-alkyle, C2-6-alcényle, C2-6-alcynyle, C3-6-cycloalkyle, NC-, HNRN-C(=O)-, C1-4-alkyl-NRN-C(=O)-, C3-6-cycloalkyl-NRN-C(=O)-, hétérocyclyl-NRN-C(=O)-, hétéroaryl-NRN-C(=O)-, HOOC-, C1-4-alkyl-O-C(=O)-, O2N-, HRNN-, C1-4-alkyl-RNN-, C1-4-alkyl-C(=O)NRN-, C3-6-cycloalkyl-C(=O)NRN-, hétérocyclyl-C(=O)NRN-, hétéroaryl-C(=O)NRN-, C1-4-alkyl-S(=O)2NRN-, C3-6-cycloalkyl-S(=O)2NRN-, hétérocyclyl-S(=O)2NRN-, hétéroaryl-S(=O)2NRN-, HO-, C1-6-alkyl-O-, HOOC-C1-3-alkyl-O-, hétérocyclyl-C1-3-alkyl-O-, phényl-C1-3-alkyl-O-, C3-6-cyclo-alkyl-O-, hétérocyclyl-O-, hétéroaryl-O-, C1-4-alkyl-S-, C3-6-cycloalkyl-S-, hétéro-cyclyl-S-, C1-4-alkyl-S(=O)-, C3-6-cycloalkyl-S(=O)-, hétérocyclyl-S(=O)-, C1-4-alkyl-S(=O)2-, C3-6-cycloalkyl-S(=O)2-, hétérocyclyl-S(=O)2-, phényl-S(=O)2-, hétéroaryl-S(=O)2-, HNRN-S(=O)2-, C1-4-alkyl-NRN-S(=O)2-, hétérocyclyle, phényle et hétéroaryle,
    dans lequel tout groupe ou sous-groupe alkyle, cycloalkyle et hétérocyclyle au sein des groupes formant R est éventuellement substitué avec 1 ou plusieurs atomes de fluor F et éventuellement substitué avec 1 à 3 groupes indépendamment sélectionné parmi Cl, C1-3-alkyle, NC-, (RN)2N-, HO-, C1-3-alkyl-O- et C1-3-alkyl-S(=O)2-; et
    dans lequel tout groupe ou sous-groupe phényle et hétéroaryle au sein des groupes formant R est éventuellement substitué avec 1 à 5 substituants indépendamment sélectionnés parmi F, Cl, C1-3-alkyle, HF2C-, F3C-, NC-, (RN)2N-, HO-, C1-3-alkyl-O-, F3C-O- et C1-3-alkyl-S(=O)2-;
    dans lequel tout groupe ou sous-groupe hétérocyclyle au sein des groupes formant
    R est sélectionné parmi
    un groupe cyclobutyle dans lequel un (1) groupe CH2 est remplacé par -NRN- or -O-;
    un groupe C5-6-cycloalkyle dans lequel un (1) groupe CH2 group est remplacé par -C(=O)-, -NRN-, -O- ou -S(=O)2- et/ou un (1) groupe CH est remplacé par N;
    un groupe C5-6-cycloalkyle dans lequel un (1) groupe CH2 group est remplacé par -NRN- ou -O-, un deuxième groupe CH2 est remplacé par -NRN-, -C(=O)- ou -S(=O)2- et/ou un (1) groupe CH est remplacé par N; et
    un groupe C5-6-cycloalkyle dans lequel deux (2) groupes CH2 sont remplacés par -NRN- ou un (1) groupe CH2 est remplacé par -NRN- et l'autre par -O- et un troisième groupe CH2 est remplacé par-C(=O)- ou -S(=O)2- et/ou un (1) groupe CH est remplacé par N;
    dans lequel tout groupe ou sous-groupe hétéroaryle au sein des groupes formant
    R est sélectionné parmi
    tétrazolyle et un cycle hétéroaromatique à 5 ou 6 chaînons qui contient 1, 2 ou 3 hétéroatomes sélectionnés indépendamment l'un de l'autre parmi =N-, -NRN-, -O- et -S-, dans lequel dans les groupes hétéroaromatiques contenant une unité -HC=N-, ce groupe-ci est éventuellement remplacé par -NRN-C(=O)-;
    dans lequel dans les cycles hétéroaryle et hétérocyclyle avec un ou plusieurs groupes NH, chacun de ces groupes NH est remplacé par NRN;
    R1 est sélectionné dans le groupe consistant en H, F, Cl, C1-4-alkyle, C3-6-cycloalkyle, HO-C1-4-alkyle, C1-4-alkyl-O-C1-4-alkyle, NC-, HO-, C1-4-alkyl-O-, C3-6-cycloalkyl-O-, C1-4-alkyl-S-, C1-4-alkyl-S(O)- et C1-4-alkyl-S(O)2-,
    dans lequel tout groupe ou sous-groupe alkyle et cycloalkyle au sein des groupes formant R1 est éventuellement substitué avec 1 ou plusieurs atomes de fluor F, et dans lequel multiples R1 peuvent être identiques ou différents, au cas où m soit 2, 3 ou 4;
    m est un nombre entier sélectionné parmi 1, 2, 3 et 4;
    R2 dénote H, F, Cl, C1-4-alkyle, NC- ou C1-4-alkyloxy,
    dans lequel tout groupe ou sous-groupe alkyle au sein des groupes formant R2 est éventuellement substitué avec 1 ou plusieurs atomes de fluor F, et dans lequel multiples R2 peuvent être identiques ou différents, au cas où n soit 2 ou 3;
    n est un nombre entier sélectionné parmi 1, 2 et 3;
    R3 dénote H, F, Cl, C1-4-alkyle, NC- ou C1-4-alkyl-O-,
    dans lequel tout groupe ou sous-groupe alkyle au sein des groupes formant R3 est éventuellement substitué avec 1 ou plusieurs atomes de fluor F;
    RN , indépendamment l'un de d'autre, est sélectionné dans un groupe consistant en H, C1-4-alkyle, HO-(C1-4-alkyl)-H2C-, C1-3-alkyl-O-C1-4-alkyle-, C1-4-alkyl-C(=O)-, C1-4-alkyl-NH-C(=O)-, C1-4-alkyl-N(C1-4-alkyl)-C(=O)-, C1-4-alkyl-O-C(=O)- et C1-4-alkyl-S(=O)2-,
    dans lequel tout groupe ou sous-groupe alkyle au sein des groupes formant RN est éventuellement substitué avec 1 ou plusieurs atomes de fluor F;
    dans lequel, dans l'une quelconque des définitions mentionnées ci-dessus, sauf indications contraire, tout groupe ou sous-groupe alkyle peut être à chaîne linéaire ou ramnifiée,
    ou un sel de celui-ci.
  2. Composé selon la revendication 1, dans laquelle
    R est sélectionné dans le groupe consistant en H, F, Cl, C1-6-alkyle, C3-6-cycloalkyle, NC-, HNRN-C(=O)-, C1-4-alkyl-NRN-C(=O)-, C3-6-cycloalkyl-NRN-C(=O)-, hétérocyclyl-NRN-C(=O)-, HOOC-, HRNN-, C1-4-alkyl-RNN-, C1-4-alkyl-C(=O)NRN-, C3-6-cycloalkyl-C(=O)NRN-, hétérocyclyl-C(=O)NRN-, C1-4-alkyl-S(=O)2NRN-, HO-, C1-6-alkyl-O-, HOOC-C1-2-alkyl-O-, hétérocyclyl-C1-2-alkyl-O-, phényl-C1-2-alkyl-O-, C3-6-cycloalkyl-O-, hétérocyclyl-O-, hétéroaryl-O-, C1-4-alkyl-S(=O)2-, C3-6-cycloalkyl-S(=O)2-, hétérocyclyl-S(=O)2-, HNRN-S(=O)2-, C1-4-alkyl-NRN-S(=O)2-, hétéro-cyclyle et hétéroaryle,
    dans lequel tout groupe ou sous-groupe alkyle, cycloalkyle et hétérocyclyle au sein des groupes formant R est éventuellement substitué avec 1 ou plusieurs atomes de fluor F et éventuellement substitué avec 1 à 2 groupes indépendamment sélectionnés parmi Cl, H3C-, NC-, RNHN-, HO-, H3C-O- et H3C-S(=O)2-;
    dans lequel tout groupe ou sous-groupe hétéroaryle au sein des groupes formant R est éventuellement substitué avec 1 à 3 substituants sélectionnés indépendamment parmi F, Cl, H3C-, F3C-, NC-, (RN)2N-, HO-, H3C-O-, F3C-O- et H3C-S(=O)2-;
    dans lequel tout groupe ou sous-groupe hétérocyclyle au sein des groupes formant
    R est sélectionné parmi
    un groupe cyclobutyle, dans lequel un (1) groupe CH2 est remplacé par -NRN- ou -O-;
    un groupe C5-6-cycloalkyle, dans lequel un (1) groupe CH2 est remplacé par -C(=O)-, -NRN-, -O- ou -S(=O)2- et/ou un (1) groupe CH est remplacé par N;
    un groupe C5-6-cycloalkyle, dans lequel un (1) groupe CH2 est remplacé par -NRN- ou -O-, un deuxième groupe CH2 est remplacé par -NRN-, -C(=O)- ou -S(=O)2- et/ou un (1) groupe CH est remplacé par N;
    dans lequel tout groupe ou sous-groupe hétéroaryle au sein des groupes formant
    R est selectionné parmi
    tétrazolyle, un cycle hétéroaromatique à 5 chaînons qui contient 1, 2 ou 3 hétéroatomes sélectionnés indépendamment l'un de l'autre parmi =N-, -NH-, O et S, et un cycle hétéroaromatique à 6 chaînons qui contient 1 ou 2 atomes d'azote =N-, dans lequel une unité -HC=N- est éventuellement remplacée par -NH-C(=O)-;
    et dans lequel dans tout groupe ou sous-groupe hétéroaryle et hétérocyclyle contenant un ou plusieurs groupes NH, le(s)dit(s) groupe(s) est/sont remplacé(s) par NRN;
    ou un sel de celui-ci.
  3. Composé selon la revendication 1, dans laquelle
    R est sélectionné dans le groupe consistant en F, Cl, NC-, H2NC(=O)-, H3CHN-C(=O)-, (H3C)2N-C(=O)-, HOOC-, H2N-, HO-;
    C1-3-alkyle éventuellement substitué avec 1 ou plusieurs F ou éventuellement monosubstitué avec HO-;
    cyclopropyle éventuellement monosubstitué avec NC-;
    H3C-O- éventuellement monosubstitué avec C1-4-alkyle, HOOC-, oxétanyle, tétrahydrofuranyle, tétrahydropyranyle, 1,1-dioxotétrahydrothiopyranyle ou phényle, dans lequel ledit groupe C1-4-alkyle est éventuellement monosubstitué avec NC-, HO- ou H3C-S(=O)2-, et dans lequel chacun desdits groupes oxétanyle, tétrahydrofuranyle, tétrahydropyranyle, 1,1-dioxotétrahydrothio-pyranyle est éventuellement monosubstitué avec H3C- ou HO-;
    cyclopropyl-O-, tétrahydrofuranyl-O- et tétrahydropyranyl-O-; et
    un groupe hétéroaryle sélectionné parmi pyrazolyle, [1,2,4]oxadiazolyle, tétrazolyle, pyridyle, pyridin-2-onyle, pyrazinyle, pyrimidinyle et pyrimidin-4-onyle, dans lequel chacun desdits groupes hétéroaryle est éventuellement monosubstitué avec H3C- et dans lequel tout groupe H-N dans lesdits groupes hétéroaryle est éventuellement remplacé avec H3C-N ou (H3C)2C(OH)-H2C-N;
    ou un sel de celui-ci.
  4. Composé selon la revendication 1, 2 ou 3, dans laquelle
    R1 est H, F, Cl, H3C-, H3C-H2C-, F3C-, NC- ou H3CO-;
    R2 est H ou F;
    R3 est H;
    m est 2 et
    n est 1;
    ou un sel de celui-ci.
  5. Composé selon la revendication 1, 2, 3 ou 4, dans laquelle R1 est H3C-; ou un sel de celui-ci.
  6. Composé selon la revendication 1, dans laquelle
    R est sélectionné dans un groupe consistant en:
    F, Cl, NC-, H2NC(=O)-, H3CHN-C(=O)-, (H3C)2N-C(=O)-, HOOC-, H2N-, HO-;
    C1-3-alkyle éventuellement substitué avec 1 ou plusieurs F ou éventuellement monosubstitué avec HO-;
    cyclopropyle éventuellement monosubstitué avec NC-;
    H3C-O- éventuellement monosubstitué avec C1-4-alkyle, HOOC-, oxétanyle, tétrahydrofuranyle, tétrahydropyranyle, 1,1-dioxotétrahydrothiopyranyle ou phényle,
    dans lequel le groupe C1-4-alkyle éventuellement attaché à H3C-O- est éventuellement monosubstitué avec NC-, HO- ou H3C-S(=O)2-, et
    dans lequel lesdits groupes oxétanyle, tétrahydrofuranyle, tétrahydropyranyle et 1,1-dioxotétrahydrothiopyranyle sont éventuellement monosubstitué avec H3C- ou HO-;
    cyclopropyl-O-, tétrahydrofuranyl-O- et tétrahydropyranyl-O-;
    un groupe hétéroaryle sélectionné parmi pyrazolyle, [1,2,4]oxadiazolyle, tétrazolyle, pyridyle, pyridin-2-onyle, pyrazinyle, pyrimidinyle et pyrimidin-4-onyle,
    dans lequel chacun desdits groupes hétéroaryle est éventuellement monosubstitué avec H3C-, et
    dans lequel tout groupe H-N dans lesdits groupes hétéroaryle est éventuellement remplacé avec H3C-N ou (H3C)2C(OH)-H2C-N;
    R1 est H, F, Cl, H3C-, H3C-H2C -, F3C-, NC- ou H3C-O-;
    m est 2;
    R2 est H ou F;
    n est 1 ; et
    R3 est H;
    ou un sel de celui-ci.
  7. Composé selon la revendication 1, dans laquelle
    R est sélectionné dans un groupe consistant en
    F, Cl, H3C-, H3C-H2C-, (H3C)2CH-,
    Figure imgb0156
     F3C-, HOCH2-, NC-, H2N-C(=O)-, H3C-NH-C(=O)-, (H3C)2N-C(=O)-, HOOC-, H2N-, HO-, H3C-O-, cyclopropyl-O-,
    Figure imgb0157
    Figure imgb0158
    Figure imgb0159
    Figure imgb0160
    Figure imgb0161
     dans lequel l'astérisque, -*, indique le point d'attachement;
    R1 est H3C-;
    m est 2;
    R2 est F;
    n est 1 ; et
    R3 est H;
    ou un sel de celui-ci.
  8. Composé selon l'une quelconque des revendications 1 à 7, avec la structure et la stéréochimie indiquées dans les formules I.1, I.2, I.3 ou I.4
    Figure imgb0162
    Figure imgb0163
    Figure imgb0164
    Figure imgb0165
     ou un sel de celui-ci.
  9. Composé selon la revendication 1 ayant l'une des structures suivantes:
    Figure imgb0166
    Figure imgb0167
    Figure imgb0168
    Figure imgb0169
    Figure imgb0170
    Figure imgb0171
    Figure imgb0172
    Figure imgb0173
     ou un sel de celui-ci.
  10. Sel pharmaceutiquement acceptable d'un composé selon l'une ou plusieurs des revendications 1 à 9.
  11. Composition pharmaceutique comprenant un ou plusieurs composés selon l'une ou plusieurs des revendications 1 à 9 ou un ou plusieurs de leurs sels pharmaceutiquement acceptables, éventuellement ensemble avec un ou plusieurs supports et/ou diluants inertes.
  12. Composé selon l'une ou plusieurs des revendications 1 à 9 ou un sel pharmaceutiquement acceptable de celui-ci pour son utilisation en tant que médicament.
  13. Composé selon l'une ou plusieurs des revendications 1 à 9 ou un sel pharmaceutiquement acceptable de celui-ci pour son utilisation dans la prévention et/ou la thérapie des maladies métaboliques et des états physiques associés avec la maladie.
  14. Composé pour son utilisation selon la revendication 13, dans laquelle la maladie métabolique est le diabète sucré et les états physiques associés avec la maladie sont la résistance d'insuline, l'obésité, une maladie cardiovasculaire ou la dyslipidémie.
  15. Composé pour son utilisation selon la revendication 13, dans laquelle la maladie métabolique est le diabète sucré de type 2.
  16. Composition pharmaceutique comprenant un ou plusieurs composés selon l'une ou plusieurs des revendications 1 à 9 ou un ou plusieurs de leurs sels pharmaceutiquement acceptables et un ou plusieurs agents thérapeutiques supplémentaires, éventuellement ensemble avec un ou plusieurs supports et/ou diluants inertes.
  17. Composition pharmaceutique selon la revendication 16, dans laquelle les agents thérapeutiques supplémentaires sont sélectionnés dans le groupe consistant en les agents antidiabétiques, les agents pour le traitement du surpoids et/ou de l' obésité et les agents pour le traitement de l'hypertension, de l'insuffisance cardiaque et/ou de l'athérosclérose.
EP16750134.5A 2015-08-07 2016-08-01 Acides indanylaminopyridylcyclopropanecarboxyliques leurs compositions pharmaceutiques et leurs utilisations Active EP3331860B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180175 2015-08-07
EP15199739 2015-12-14
PCT/EP2016/068291 WO2017025368A1 (fr) 2015-08-07 2016-08-01 Acides indanylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3331860A1 EP3331860A1 (fr) 2018-06-13
EP3331860B1 true EP3331860B1 (fr) 2019-07-17

Family

ID=56618142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16750134.5A Active EP3331860B1 (fr) 2015-08-07 2016-08-01 Acides indanylaminopyridylcyclopropanecarboxyliques leurs compositions pharmaceutiques et leurs utilisations

Country Status (4)

Country Link
US (1) US9617251B2 (fr)
EP (1) EP3331860B1 (fr)
JP (1) JP6816107B2 (fr)
WO (1) WO2017025368A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312706B (zh) 2016-11-28 2023-08-18 勃林格殷格翰国际有限公司 茚满基氨基吡啶基环丙烷甲酸、其药物组合物及用途
CN110214135B (zh) * 2017-01-26 2023-02-21 勃林格殷格翰国际有限公司 茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
JOP20180040A1 (ar) * 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
BR102019002873A2 (pt) 2018-02-13 2019-09-10 Gilead Sciences Inc inibidores de pd-1/pd-l1
EP3755311A4 (fr) 2018-02-22 2021-11-10 ChemoCentryx, Inc. Indane-amines utiles en tant qu'antagonistes de pd-l1
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7212409B2 (ja) * 2018-10-10 2023-01-25 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー カルベン化合物、カルベン‐金属ナノ粒子複合体およびその製造方法
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2021071837A1 (fr) 2019-10-07 2021-04-15 Kallyope, Inc. Agonistes de gpr119
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559422B1 (fr) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Agent de controle de la fonction recepteur
CA2560111A1 (fr) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Derive de l'acide aminophenylpropanoique
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US8633182B2 (en) * 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
US20160200734A1 (en) * 2013-08-23 2016-07-14 Xinshan Kang Carboxylic acid compounds in treatment of diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP3331860A1 (fr) 2018-06-13
US20170037040A1 (en) 2017-02-09
WO2017025368A1 (fr) 2017-02-16
JP2018526352A (ja) 2018-09-13
US9617251B2 (en) 2017-04-11
JP6816107B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
EP3331860B1 (fr) Acides indanylaminopyridylcyclopropanecarboxyliques leurs compositions pharmaceutiques et leurs utilisations
EP3580222B1 (fr) Acides indanylaminoazadihydrobenzofuranylacétiques, compositions pharmaceutiques pour le traitement du diabète
EP3573959B1 (fr) Acides benzylaminopyrazinylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées
EP3573952B1 (fr) Acides benzylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées
EP3347358B1 (fr) Acides [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acétiques, compositions pharmaceutiques et utilisations associées
EP3532458B1 (fr) Acides benzylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations
EP3573965B1 (fr) Acides indanylaminopyrazinylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations
EP3544958B1 (fr) Acides indanylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations
US10913720B2 (en) Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3573969A1 (fr) Acides benzyloxypyrazinylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190311

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016017049

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1155729

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190815

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190717

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1155729

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191118

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191017

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191017

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191117

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191018

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190801

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016017049

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190801

26N No opposition filed

Effective date: 20200603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240821

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240826

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240829

Year of fee payment: 9